Synergistic effects of unacylated ghrelin and endurance exercise on sarcopenia and mobility loss

Active Project Grant Awarded Last action

Award ID
R01AG092766
Recipient
Awarding agency
Obligated
$1,310,841

Award facts

Assistance listing
93.866 Aging Research
Completion date 16% complete
Place of performance
Winston-Salem, NC 27157, USA

Award details come from USAspending.gov.

About this award

The National Institute on Aging awarded Wake Forest University Health Sciences $1.31 million on February 1, 2026, under the Aging Research program (CFDA 93.866) to investigate the synergistic effects of unacylated ghrelin and endurance exercise on sarcopenia and mobility loss in older adults.

The research combines unacylated ghrelin (UNAG) administration with endurance exercise training to enhance mitochondrial bioenergetics and preserve neuromuscular junction integrity in aging mice. Preliminary data indicates that UNAG combined with endurance exercise additively increases mitochondrial bioenergetics while synergistically improving motor coordination, muscle mass, and contractile function by activating both shared pathways (PGC-1A) and distinct pathways (mTORC2) compared to endurance exercise alone. The study addresses sarcopenia—the progressive loss of muscle mass and function—which universally impacts aging populations and contributes to loss of mobility and independence in older adults.

Work is performed in Winston-Salem, North Carolina, with a period of performance from February 1, 2026, through January 31, 2031. The funding obligates $1.31 million as a Project Grant, the standard assistance type for investigator-initiated research under the Aging Research program.

Description

Abstract
Sarcopenia, the progressive loss of muscle mass and function, universally impacts the aging population, contributing to loss of mobility and independence in older adults. With the rapid growth of the aging population, there is an urgent need for effective strategies against sarcopenia. Exercise is the most effective intervention that increases muscle mass and function in younger adults, but its benefits are attenuated in older adults due to diminished responses to exercise training. Over the years, several candidate molecules, including metformin, antioxidants, and resveratrol were combined with endurance exercise (EE) in an attempt to increase training- induced benefits; however, these interventions failed to enhance training responses and, in some cases, reduced the positive effects of exercise. Given metformin's inhibitory effects on mitochondrial respiration and the ability of antioxidants to scavenge signaling molecules in response to exercise, a logical next step is to combine EE with a candidate molecule that specifically enhances mitochondrial bioenergetics and its downstream pathways. A strong such candidate is unacylated ghrelin (UNAG), whose circulating levels are significantly decreased in older adults and mice. Our pilot data provides evidence that UNAG combined with endurance exercise (UNAG+EE) additively increases mitochondrial bioenergetics, while synergistically improving motor coordination, muscle mass and contractile function. Our data also revealed that UNAG activated both shared (i.e., PGC-1Α) and distinct (i.e., MTORC2) pathways compared to those triggered by EE alone, suggesting that UNAG+EE may provide synergistic and complementary benefits. Building on our compelling preliminary data, we hypothesized that the combination of UNAG+EE will enhance mitochondrial bioenergetics and preserve NMJ integrity in older mice, providing synergistic protection for sarcopenia. Our specific aims will focus on the effects of UNAG, EE, and UNAG+EE on mitochondrial bioenergetics and oxidative stress (aim 1), motor neuron cell numbers and inflammation in the spinal cord and neuromuscular junction (aim 2), and muscle mass, function, and protein quality in skeletal muscle (aim 3) in older mice. We will also assess additive or synergistic effects of UNAG+EE on key endpoint measures for each aim. Transcriptomic analysis will be performed to identify differentially expressed genes and pathways influenced by our interventions, which can provide essential information for mechanistic investigations in the future. If our results support the hypothesis, UNAG+EE will be the first combination therapy that shows additive or synergistic effects for sarcopenia. UNAG+EE also has great potential for translation, given the established safety of UNAG and its mimetics in humans. Finally, our proposal aligns directly with the current strategic directions of the NIA, "develop effective interventions to maintain health, well- being, and function, while preventing or reducing the burdens of age-related diseases, disorders, and disabilities.

Transactions

Action Obligated Date
Amendment $111,595
Amendment $599,623
Original award $599,623

Subawards

Subrecipient Amount Awarded
Oklahoma Medical Research Foundation Dr. Benjamin Miller will advise on study design for stable isotopic tracing and proteomic analyses. His lab will perform all analyses on these samples. The… $43,431

Quick answers

Who received award R01AG092766?

R01AG092766 was awarded to Wake Forest University Health Sciences by National Institute on Aging (National Institutes of Health) on February 1, 2026.

How much is award R01AG092766 worth?

$1,310,841 has been obligated on R01AG092766.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award